Wednesday 20 October 2010

Novozymes wins P&G’s Supplier of the Year award for the third consecutive year

MONTREUX, SWITZERLAND – October 11, 2010 – Procter & Gamble (P&G), the largest consumer goods company in the world, recognizes Novozymes as one of its most outstanding suppliers.

Out of P&G’s 80,000 suppliers, Novozymes was one of 76 supplier and agency partners who were awarded an “Excellence Award.” Of those, Novozymes was one of only six companies recognized with the prestigious “Supplier of the Year” award. This was due to its strong commitment to innovation and supply excellence, which is a benchmark for the industry.
P&G announced the award winners during a celebration Thursday evening in connection with the 2010 Supplier and Agency Summit. This followed a P&G Supplier Award event at the 7th World Conference on Detergents which took place in Montreux, Switzerland, last week, where Novozymes was presented the Supplier of the Year trophy.

“We’re honored to win this award once again because it clearly shows that Novozymes’ customers value our commitment to developing innovative solutions. These awards indicate that we're delivering at a very high level and that our customers see us as partners and as instrumental to their business,” says Peder Holk Nielsen, Executive Vice President for Enzyme Business at Novozymes.

Since 2008, P&G has committed to meeting annually with its top-performing suppliers to recognize and celebrate those partners that have demonstrated their excellence in a number of categories associated with commercial, operational, innovation, and relationship performance. Novozymes has won the Supplier of the Year award every year since 2008.

Albufuse

Half-life extension through albumin fusion technology

A simple, single step expression platform for the production of proteins with extended half-life. Avoids post-production costs associated with chemical processing such as PEGylation.

Combine albumin fusion albufuse with our yeast expression technology and cGMP/Q7-manufacturing services to maximize the benefits of working with us.

Key benefits

  • Increased half-life of the active molecule, resulting in:
    • Less frequent administration
    • Increased bioavailability therefore lowered dosage
  • Fewer side effects with improved tolerance
  • Competitive production costs
  • Specific albumin fusion binding matrices available for improved downstream purification
  • Animal-free
  • Genetically fused.

Application areas

Recombumin

The future of formulation is clear!

The world’s first and only, animal-free, commercially available recombinant human albumin, approved for use in the manufacture of human therapeutics.

Used in the manufacture of the FDA and EMEA approved M-M-R™ II childhood vaccine from Merck and Co., Recombumin* is also being evaluated as an excipient, or ingredient, in several other products undergoing clinical development in the US and EU. 

Key benefits

  • Stabilize your product in liquid formulation at room temperature
  • Improve visual appearance of lyophilized product and decrease dissolution time
  • Manufactured to Q7 GMP in FDA, Health Canada and MHRA inspected facilities
  • Extend product bioavailability
  • Half-life extension of peptides.

Application areas